Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Modification of Sexual Hormones in Rheumatoid Arthritis Patients by M2000 (Β-D-Mannuronic Acid) As a Novel Nsaid With Immunosuppressive Property Publisher Pubmed



Jahanbakhshi M1, 7 ; Babaloo Z2, 3 ; Mortazavijahromi SS1, 4 ; Shokri MM5 ; Ahmadi H1 ; Mirshafiey A1
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
  2. 2. Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
  3. 3. Immunology Department, Medicine Faculty, Tabriz University of Medical Sciences, Tabriz, Iran
  4. 4. Department of Cellular and Molecular Biology, Kish International Campus, University of Tehran, Kish, Iran
  5. 5. International Sturgeon Research Institute, Agricultural
  6. 6. Research, Education & Extension Organization (AREEO), Rasht, Iran
  7. 7. Department of Biology, Science and Research Branch, Islamic Azad University, Tehran, Iran

Source: Endocrine# Metabolic and Immune Disorders - Drug Targets Published:2018


Abstract

Background: Based on in-vitro, in-vivo and human studies, the β-D-mannuronic acid (M2000) has been introduced as a novel non-steroidal anti-inflammatory drug (NSAID) with immunosuppressive properties. Objective: This study aimed to evaluate the efficacy of this drug on serum level of sex hormones (Es-tradiol, Progesterone, and DHEAS) in rheumatoid arthritis (RA) patients. Methods: The present research was performed on 10 RA patients who had an inadequate response to conventional treatments (clinical trial identifier: IRCT2014011213739N2). During this trial, the patients were permitted to continue the conventional therapy along with adding M2000 orally at a dose of 500 mg twice daily for 12 weeks. Serum samples were collected in a normal group, patient group (at baseline) and treatment group (after 12 weeks). The samples were tested for evaluating the serum level of Estradiol, Progesterone, and DHEAS using chemiluminescent microparticle immunoassay. Results: Data showed that the serum level of estradiol was reduced (both in men and women) during the treatment with M2000 (after 12 weeks), but there was no significant difference in the non-treated group with M2000 (p > 0.05). In addition, the serum level of progesterone and DHEAS significantly increased following the 12-week administration of M2000 in both male and female patients, compared to the non-treated group with M2000 (p < 0.001, p < 0.05, p < 0.05, p < 0.01, respectively). Conclusion: The present research showed that the sex hormones might be modified by M2000 therapy in RA patients by increasing the serum level of progesterone and DHEAS compared to healthy individuals. © 2018 Bentham Science Publishers.
Experts (# of related papers)
Other Related Docs
34. Β-D-Mannuronic Acid (M2000) As a Landmark in Pharmacology, Current Drug Discovery Technologies (2021)
44. Β-D-Mannuronic Acid (M2000) and Inflammatory Cytokines in Covid-19; an in Vitro Study, Iranian Journal of Allergy# Asthma and Immunology (2022)